View By Speaker
M. Agronin, MD
M. Alexander, PhD, MA
S. Ancoli-Israel, Ph.D
L. Boesky, PhD
R. Brown, PhD
A. Burstein, MD
R. Dougherty, PhD
J. Draud, MD, MS
P. Earley
G. Emslie, MD
L. Ereshefsky, PharmD
M. Forstein, MD
A. Frances, MD
M. Gold, MD
D. Goodman, MD
K. Gray, MD
D. Greenberg, MD
D. Greydanus, MD
R. Hendren, DO
R. Jackson, MD
R. Jain, MD, MPH
S. Jain, PsyD, LPC, MBA
J. Kane, MD
S. Katz, MSN PMH-CNS, BC
L. Kinsella, MD, FAAN
A. Krystal, MD
S. Levine, MD
J. Maldonado, MD
V. Maletic, MD, PA
B. McCarberg, MD
J. McGough, MD, MS
L. Miller, MD
L. Nagy, MD
H. Nasrallah, MD
S. Negi, MA, PhD
J. Nelson, MD
J. Newcomer, MD
G. Papakostas, MD
M. Piasecki, MD
J. Prince, MD
C. Raison, MD
P. Resnick, MD
A. Robb, MD
C. Rodgers, MD
M. Rosenberg, MD, PhD
J. Schim, MD
D. Schuyler, MD
S. Shea, MD
T. Simpatico, MD
T. Skale, MD
B. Smith, JD
T. Smith, MS Psych, PD, FASCP, LMHC, NCP
S. Sobel, MD
D. Sprague
M. Stein, MD, MPH
R. Stille, MBA
V. Strasburger, MD
John Tsuang, MD
S. Verma, MD
J. Victoroff, MD, MA
J. Weiner, MD, PhD
S. Yaffe, MD
A. Young, MD, MSHS
|
John Tsuang, MDClinical Professor, Psychiatry and Biobehavioral Science, Harbor-UCLA Medical Center| Thursday, November 5 09:15-10:30 a.m. |
427 - Club Drugs and Their Psychiatric Manifestations RX PD NP
1.25 credits - Room: Lagoon ABCGHI |
John Tsuang, MD, Clinical Professor, Psychiatry and Biobehavioral Science, Harbor-UCLA Medical Center
|
This talk explores the ongoing concerns about the increase in the popularity of a socially designated class of drugs known as "club drugs." By participating in this activity, attendees will be able to: - Discuss the major categorization of club drugs and their pharmacological properties;
- Identify the clinical and psychiatric manifestations of club drugs; and
- Recognize available treatment approaches and harm reduction and prevention strategies.
|
| Thursday, November 5 10:45-12:00 p.m. |
434 - Pharmacology of Dual Diagnosis Patients RX PD
1.25 credits - Room: Lagoon ABCGHI |
John Tsuang, MD, Clinical Professor, Psychiatry and Biobehavioral Science, Harbor-UCLA Medical Center
|
Upon the completion of this activity, participants will be able to: - Describe the relative risk of comorbid substance abuse with other psychiatric syndromes.
- Identify the available pharmacological agents for treatment of dual-diagnosis patients and medication treatment for substance dependence disorders.
- Discuss the difficulties relating to the treatment and the harm reduction model vs. the abstinence model for dual-diagnosis patients.
|
|
